Placeholder Banner

BIO Statement on Proposed Maryland Drug Pricing Legislation

January 10, 2017

Washington, D.C. (January 10, 2017) – The Biotechnology Innovation Organization today released the following statement regarding proposed drug pricing legislation within the Maryland Senate:

“Any legislative effort to address the affordability of medicines must be patient centered, holistic, and promote patient access to treatments and cures. Biotechnology innovation is not only providing enormous benefits to patients and value to the healthcare system, but it is a proven job creator, employing over 34,000 Marylanders in good, high-paying jobs, with billions invested in the state annually. BIO will oppose legislative proposals that could harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through heavy-handed government intrusion.”

###

Discover More
Public opinion polls show there is significant mistrust among the American public in the safety and efficacy of vaccines. So today, the Biotechnology…
Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission…
Washington, DC (November 20, 2020) – Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose…